Pasireotide

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Carcinoid Tumor

Conditions

Carcinoid Tumor, Acromegaly

Trial Timeline

Jun 1, 2006 → Nov 1, 2013

NCT ID

NCT00446082

About Pasireotide

Pasireotide is a phase 1 stage product being developed by Novartis for Carcinoid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT00446082. Target conditions include Carcinoid Tumor, Acromegaly.

What happened to similar drugs?

1 of 9 similar drugs in Carcinoid Tumor were approved

Approved (1) Terminated (1) Active (7)

🔄Pasireotide + OctreotideNovartisPhase 3

🔄Octreotide + Placebo + EverolimusNovartisPhase 3

❌lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3

✅lanreotide (Autogel formulation)IpsenApproved

🔄Lanreotide + PlaceboIpsenPhase 3

🔄Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3

🔄Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03103009	Phase 1	Completed	Mar 22, 2017	Dec 22, 2017	Hyperinsulinemic Hypoglycemia
NCT02780882	Phase 2	Withdrawn	Dec 1, 2015	Jun 1, 2019	Ectopic ACTH Syndrome
NCT01617733	Phase 2	Terminated	Mar 1, 2011	Dec 1, 2015	Nelson Syndrome
NCT00698464	Phase 1	Completed	Jul 1, 2008	—	Hepatic Cirrhosis
NCT00434148	Phase 3	Completed	Dec 1, 2006	May 1, 2014	Cushing's Disease
NCT00446082	Phase 1	Completed	Jun 1, 2006	Nov 1, 2013	Carcinoid Tumor
NCT00171730	Phase 2	Completed	Aug 24, 2004	Dec 6, 2013	Acromegaly
NCT00171951	Phase 2	Completed	Aug 13, 2004	Jul 8, 2013	Cushing Disease

Competing Products

20 competing products in Carcinoid Tumor

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab + Somatostatin Analog	Eli Lilly	Phase 2	35
Pasireotide + Octreotide	Novartis	Phase 3	40
Pasireotide (SOM230)	Novartis	Phase 2	35
Octreotide + Placebo + Everolimus	Novartis	Phase 3	40
Lutathera	Novartis	Phase 2	27
EPO906 epothilone B	Novartis	Phase 2	35
Panitumumab	Amgen	Phase 2	27
Axitinib	Pfizer	Phase 2	35
Lanreotide + Placebo (for sunitinib) + Sunitinib	Pfizer	Phase 2	31
Nivolumab + Cabozantinib	Bristol Myers Squibb	Phase 2	35
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin	Sanofi	Phase 2/3	30
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)	Ipsen	Phase 3	29
lanreotide (Autogel formulation)	Ipsen	Approved	40
Lanreotide + Placebo	Ipsen	Phase 3	37
BIM 23A760	Ipsen	Phase 2	24
Randomized: 40 mg Paltusotine + Randomized: 80 mg Paltusotine	Crinetics Pharmaceuticals	Phase 2	32
Paltusotine + Placebo	Crinetics Pharmaceuticals	Phase 3	44
Telotristat etiprate + Placebo-matching telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	34
Telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	34
500 mg [14C]-LX1606	Lexicon Pharmaceuticals	Phase 1	23